IONIS PHARMACEUTICALS INC (IONS) Stock News

USA - NASDAQ:IONS - US4622221004 - Common Stock

72.67 USD

+0.22 (+0.3%)

Last: 11/12/2025, 8:00:02 PM

72.58 USD

-0.09 (-0.12%)

After Hours: 11/12/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IONS Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Ionis Pharmaceuticals, Inc.

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

2 days ago - By: Benzinga

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

3 days ago - By: Benzinga - Mentions: SRDX WORX GTBP IFRX ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

5 days ago - By: Ionis Pharmaceuticals, Inc.

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

6 days ago - By: Investor's Business Daily - Mentions: RY RY.CA NTLA CRSP ...

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

7 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

2 months ago - By: Stocktwits - Mentions: EAOR PBE

News Image

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

14 days ago - By: Zacks Investment Research - Mentions: AZN NVS BIIB

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

14 days ago - By: The Motley Fool

Ionis (IONS) Q3 2025 Earnings Call Transcript

14 days ago - By: Investor's Business Daily - Mentions: PFE ALNY BBIO AZN

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.

15 days ago - By: Zacks Investment Research

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

15 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis reports third quarter 2025 financial results and highlights progress on key programs

17 days ago - By: Ionis Pharmaceuticals, Inc.

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

20 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

23 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

23 days ago - By: The Motley Fool - Mentions: WAY TARS MSFT VERA ...

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis to hold third quarter 2025 financial results webcast

a month ago - By: Investor's Business Daily - Mentions: GILD

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

2 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

2 months ago - By: Ionis Pharmaceuticals, Inc.

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

2 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

2 months ago - By: Zacks Investment Research - Mentions: RARE ADPT AKRO

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis to host investors and analysts for Innovation Day 2025